Mengzhu Yang

Nanjing Medical University — China

Medicine · Health Sciences

11h-index403citations33works1.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(12), Cancer Treatment and Pharmacology(8), Breast Cancer Treatment Studies(7), Composite Structure Analysis and Optimization(3), Cancer Cells and Metastasis(3)

Publications33 total

Multi-omics analysis of NET+ TAN explains the immunosuppressive TME and prognosis value of malignant clinical characteristics in TNBC
Translational Oncology·2026Open Access
Topology Optimization of NURBS-Based Composite Shells with An Integrated Bidirectional Parametric Physical Co-Design Strategy
SSRN Electronic Journal·2025Open Access
A novel multi-stage concurrent topology optimization for variable-stiffness structures
Journal of Composite Materials·2024
Validation of risk assessment scores in predicting venous thromboembolism in patients with lung cancer receiving immune checkpoint inhibitors
BMC Pulmonary Medicine·2024· 7 citedOpen Access
A Novel Multi-Stage Concurrent Topology Optimization For Variable-Stiffness Structures
SSRN Electronic Journal·2024Open Access
DJ-1: A Potential Biomarker Related to Prognosis, Chemoresistance, and Expression of Microenvironmental Chemokine in HR-Positive Breast Cancer
Journal of Immunology Research·2023· 2 citedOpen Access
A novel multi-stage concurrent topology optimization for variable-stiffness structures
arXiv (Cornell University)·2023Open Access
Large Impact of Small Vertex Cuts on the Mechanics of Origami Bellows
arXiv (Cornell University)·2022· 2 citedOpen Access
MKL1 is a key biomarker correlated with immune infiltrates and chemosensitivity in breast cancer
Bosnian Journal of Basic Medical Sciences·2021· 1 citedOpen Access
Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study
Cancer Medicine·2021· 19 citedOpen Access
A Prospective, Single-Arm, Phase II Trial of Apatinib Combined With Nab-Paclitaxel and Carboplatin for The Neoadjuvant Treatment of Triple-Negative Breast Cancer
Research Square (Research Square)·2021Open Access
High Rate of Epidermal Growth Factor Receptor-Mutated Primary Lung Cancer in Patients with Primary Breast Cancer
Research Square (Research Square)·2021Open Access
Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials
Annals of Translational Medicine·2021· 20 citedOpen Access
Risk Signature of Cancer-Associated Fibroblast–Secreted Cytokines Associates With Clinical Outcomes of Breast Cancer
Frontiers in Oncology·2021· 16 citedOpen Access
P16-3 Maintenance therapy in HER2 and hormone receptor-positive breast cancer
Annals of Oncology·2021
Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis
Journal of Experimental & Clinical Cancer Research·2021· 41 citedOpen Access
Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer
Frontiers in Pharmacology·2020· 9 citedOpen Access
MKL1 Mediates TGF-β Induced RhoJ Transcription to Promote Breast Cancer Cell Migration and Invasion
Frontiers in Cell and Developmental Biology·2020· 28 citedOpen Access
Long non-coding RNA SNHG1 activates HOXA1 expression via sponging miR-193a-5p in breast cancer progression
Aging·2020· 50 citedOpen Access
Relationship between <scp>tRNA</scp>‐derived fragments and human cancers
International Journal of Cancer·2020· 84 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Yongmei Yin(19), Chunxiao Sun(18), Ziyi Fu(18), Tianyu Zeng(15), Fan Yang(12), Xiang Huang(11), Jun Li(11), Hao Wu(10), Yongfei Li(9), Yijia Hua(8), Wěi Li(8), Biyun Wang(6), Feng Jin(6), Haibo Wang(6), Peifen Fu(6), Zefei Jiang(6), Xueqi Yan(5), Shengnan Bao(5), Yiqi Yang(4), Fan Yang(4)